Reducing Advanced Melanoma with Tebentafusp and Other Treatment Options
NCT05549297 · RecruitingThis study looks at how well tebentafusp works in treating advanced melanoma. Participants will receive either tebentafusp alone, tebentafusp with another drug called pembrolizumab, or the doctor's choice of treatment. The goal is to see which option is more effective and safe for patients who have already received other treatments.
Locations and contact
This trial is running at 82 locations. The first 8 are listed here.
- Mayo Clinic ArizonaPhoenix, ArizonaRecruiting
- Mayo Clinic FloridaJacksonville, FloridaRecruiting
- Orlando Health Cancer InstituteOrlando, FloridaRecruiting
- Winship Cancer Institute of Emory UniversityAtlanta, GeorgiaRecruiting
- University of Kansas Cancer Center - WestwoodWestwood, KansasRecruiting
- St Elizabeth Healthcare (St Elizabeth Medical Center)Edgewood, KentuckyRecruiting
- St Elizabeth Healthcare (St Elizabeth MedicalEdgewood, KentuckyRecruiting
- Massachusetts General HospitalBoston, MassachusettsRecruiting
Who can join
Adults aged 18 and older can join this trial. It is open to men and women who have a specific type of melanoma that can't be removed by surgery. Participants must be able to provide tumor samples and meet other health criteria. The trial team will confirm who is eligible to participate.
What happens during the trial
Participants will be placed into one of three groups by chance. - Arm A will receive tebentafusp alone. - Arm B will receive tebentafusp along with pembrolizumab. - Arm C will receive the treatment chosen by their doctor. Everyone will be monitored for their health during the study.
The trial team
The trial is sponsored by Immunocore Ltd. They are responsible for running the study and ensuring everything is done correctly.
Important dates
The trial started on December 19, 2022, and is currently enrolling new participants. It is expected to finish by July 2028.
Additional information
This is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. The trial hopes to include around 540 participants and is regulated by the FDA.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →